FDA Oks Eli Lilly's Selpercatinib For Medullary Thyroid Cancer
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Eli Lilly's drug Selpercatinib for the treatment of medullary thyroid cancer, which could positively impact the company's stock.
September 27, 2024 | 7:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly received FDA approval for its drug Selpercatinib, targeting medullary thyroid cancer. This approval could enhance Eli Lilly's product portfolio and potentially boost its stock price.
FDA approval of a new drug typically leads to positive investor sentiment as it can lead to increased sales and revenue. Selpercatinib's approval for medullary thyroid cancer adds to Eli Lilly's oncology portfolio, potentially driving growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100